# Carl Whatley

> Carl L. Whatley Jr. is an Alabama pharmaceutical entrepreneur who moved from a two-decade sales career at Wyeth into founding, building and selling specialty and generic drug businesses. He founded ProEthic Laboratories in 2001 and Midlothian Laboratories in 2002, sold both businesses in 2007-08, briefly led Kowa Pharmaceuticals America, formed the consulting firm Cendalor in 2010 and co-founded Vitruvias Therapeutics in 2013. His operating pattern centered on overlooked products, licensing partnerships and the commercial work required to bring generic pharmaceuticals to the United States; Vitruvias announced in 2026 that it had ceased operations and that its products were owned or distributed by H2-Pharma.

- **Role:** Chairman, CEO & Co-Founder at Vitruvias Therapeutics through its 2026 cessation of operations
- **Organizations:** Vitruvias Therapeutics, Cendalor LLC, Kowa Pharmaceuticals America, ProEthic Laboratories, Midlothian Laboratories, Wyeth
- **Education:** B.A. in History, Auburn University at Montgomery, University of Alabama
- **Known for:** Built ProEthic from five employees and one product to 113 employees and 15 products between 2002 and 2005, with reported revenue reaching $25 million in 2005., Named the 2006 Alabama Small Business Person of the Year., Recognized as a finalist in the 2006 American Business Awards Best Chairman category.

## Career timeline

- **1980** — Began his pharmaceutical career as a sales representative with Wyeth, now part of Pfizer.
- **2001** — Left Wyeth after 21 years and founded ProEthic Laboratories, focused on branded specialty prescription products.
- **2002** — Founded Midlothian Laboratories to focus on the generic prescription market.
- **2006** — Named Alabama Small Business Person of the Year for his work at ProEthic.
- **2007** — Divested Midlothian Laboratories to Hi-Tech Pharmacal.
- **2008** — ProEthic was acquired by Japan's Kowa Company; Whatley continued as chairman and CEO of Kowa Pharmaceuticals America.
- **2009** — Left Kowa and entered a short-lived retirement.
- **2010** — Formed Cendalor LLC, a boutique management consulting and investment-analysis firm serving pharmaceutical and medical-food companies.
- **2013** — Co-founded Vitruvias Therapeutics with Bryce Harvey.
- **2018** — Vitruvias completed an $11.5 million Series A financing led by JW Asset Management and Perceptive Advisors.
- **2023** — Vitruvias announced a U.S. commercialization collaboration with PharmaTher.
- **2026** — Vitruvias stated that it had ceased operations and that all products were owned or distributed by H2-Pharma.

## Achievements

- Built ProEthic from five employees and one product to 113 employees and 15 products between 2002 and 2005, with reported revenue reaching $25 million in 2005.
- Named the 2006 Alabama Small Business Person of the Year.
- Recognized as a finalist in the 2006 American Business Awards Best Chairman category.
- Founded and successfully divested both Midlothian Laboratories and ProEthic Laboratories.
- Co-founded Vitruvias Therapeutics and raised an $11.5 million Series A round in 2018.
- Built cross-border pharmaceutical development and commercialization partnerships involving firms in Taiwan, Hong Kong, Canada and other markets.

## Latest updates

- **2026-08** — Vitruvias Therapeutics stated on its website that it had ceased operations and that all products were now owned or distributed by H2-Pharma.
- **2023-06** — Vitruvias entered a collaboration with PharmaTher for U.S. commercialization of KETARX.

## Links

- Website: https://www.vitruvias.com
- LinkedIn: https://www.linkedin.com/in/carl-whatley-6960037

---

Profile page: https://yespress.io/carl-whatley
Published by YesPress — https://yespress.io
Last updated: 2026-08-27